post-comment
Comment
post-Abuse

Do you want to report this message as spam?

Ranbaxy transfers drug discovery unit to Daiichi Sankyo

03 Jul 10 11:10 AM
Money Control
In a bout of restructuring, pharma major Ranbaxy today announced that their New Drug Discovery Research (NDDR) has been transferred to Daiichi Sankyo India Pharma Private Limited under the rationale of strengthening the global R&D of Daiichi Sankyo Group.

The new company formed will be Daiichi Sankyo Life Science Research Center (RCI). NDDR will become a part of RCI. Ranbaxy will continue to independently develop and later commercialize the anti-malarial drug which is in Phase III. It will explore further development of late stage programs developed by NDDR including development programmes with the GSK collaboration.